Click here to read full article…
Study on Plaxgen
Alzheimer’s disease blood
diagnostic published in
peer-reviewed journal
BY LLOYD DUNLAP
SUNNYVALE, Calif.—Plaxgen Inc., a developer
of flow cytometry-based blood diagnostics for
plaque-associated illnesses such as atherosclerosis
and Alzheimer’s disease, announced that a paper
validating its Plaque Array technology for the diagnosis
of Alzheimer’s disease was published in the
peer-reviewed journal Clinica Chimica Acta.
In a study titled “Plaque Array Method and Proteomics-
based Identification of Biomarkers from
The erection is not viagra prescription free as rigid or hard as a natural erection; drugs or injections, when they work, may be preferable. The L-Arginine Benefits for Health: So what additional L-Arginine benefits should you know about? First, L-Arginine can be help boost the invention online cialis mastercard http://ronaldgreenwaldmd.com/procedures/ of nitric oxide in spongy tissues of penis which results in quicker and firmer erections. Men have become aware of the fact that ED, although incurable, is treatable with effective oral medicine. viagra prices online To know more about kamagra and its potential benefits, please talk to a qualified viagra soft 50mg doctor. Alzheimer’s Disease Serum,” researchers concluded
that the Plaque Array methodology developed by
Plaxgen works well for detecting amyloid beta
(Abeta) and other particle formation in the blood
serum of subjects clinically determined to have
Alzheimer’s disease (AD).
As stated in the paper’s abstract, progressive
accumulation of amyloid plaques in the regions
of brain, carotid and cerebral arteries is the leading
cause of Alzheimer’s disease and related dementia
in affected patients. The early identification
of individuals with AD remains a challenging
task reliant on symptomatic events, and thus the
development of a biomarker-based approach will
significantly aid in the diagnosis of AD.